Ismael Martos-Jamai

Ismael Martos-Jamai

Auto-generated profile, based on publicly available information

Ismael Martos-Jamai

GENYO, Centre for Genomics and Oncological Research, Pfizer, University of Granada, Andalusian Regional Government, PTS Granada , Avenida de la Ilustración, 114, Granada 18016

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2026 in Nucleic Acids Research
Verified
Journal Article
Open access
AAAraceli Aguilar-González
Araceli Aguilar-González
IMIsmael Martos-Jamai
Ismael Martos-Jamai
IRIris Ramos-Hernández
Iris Ramos-Hernández
FMFrancisco Javier Molina-Estévez
Francisco Javier Molina-Estévez
NVNancy Villegas Villao
Nancy Villegas Villao
Francisco MartinFrancisco Martin
Francisco Martin
The emergence of CRISPR–Cas systems has transformed nucleic acid detection and manipulation. Cas13, a type VI CRISPR effector, targets RNA with high sensitivity through both cis (target RNA) and trans (collateral RNA) cleavage. This property enables the use of fluorescent reporters for sensitive diagnostics. However, Cas13’s heightened sensitivity also leads to reduced specificity due to its susceptibility to single-nucleotide mismatches, potentially causing off-target effects. To overcome this limitation, we developed the first Dual-guide RNA system for Cas13 that improves mismatch discrimination and enhances target specificity. This system employs two distinct RNAs—dcrRNA and dtracrRNA—which cooperatively recognize the target and reduce off-target activity. In vitro experiments demonstrated robust cis- and trans-RNase activity, indicating efficient and specific cleavage. The system accurately detected SARS-CoV-2 RNA, distinguished KRAS G12D and G12C mutations, and differentiated mucocutaneous from cutaneous Leishmania sequences in analytical assays, with clinical validation confirming accurate detection of positive and negative samples. These results highlight the Dual-guide Cas13 platform’s potential for precise, rapid, and reliable RNA detection. Overall, this approach represents a substantial advance over conventional Cas13 systems, offering improved specificity while maintaining clinically relevant sensitivity, and provides a generalizable tool for next-generation molecular diagnostics and precision RNA targeting and regulation.

27 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
AAAraceli Aguilar-González
Araceli Aguilar-González
IMIsmael Martos-Jamai
Ismael Martos-Jamai
IRIris Ramos-Hernández
Iris Ramos-Hernández
FMFrancisco Javier Molina-Estévez
Francisco Javier Molina-Estévez
PPPilar Puig-Serra
Pilar Puig-Serra
Francisco MartinFrancisco Martin
Francisco Martin
The emergence of CRISPR-Cas systems has transformed nucleic acid detection and manipulation. Cas13, a type VI CRISPR effector, targets RNA with high sensitivity through both cis (target RNA) and trans (collateral RNA) cleavage. This property enables the use of fluorescent reporters for sensitive diagnostics. However, Cas13’s heightened sensitivity also leads to reduced specificity due to its susceptibility to single-nucleotide mismatches, potentially causing off-target effects. To overcome this limitation, we developed the first dual-guide RNA system for Cas13 that enhances mismatch discrimination and improves target specificity. This system employs two distinct RNAs—dcrRNA and dtracrRNA—which hybridise to refine target recognition and activation. In vitro experiments demonstrated robust cis- and trans-RNase activity, indicating efficient and specific cleavage. The system accurately detected SARS-CoV-2 RNA, demonstrating its potential for pathogen diagnostics, and successfully discriminated between KRAS G12D and G12C mutations—clinically relevant single-nucleotide variants in cancer diagnosis. These results highlight the dual-guide Cas13 platform’s potential for precise, rapid, and reliable RNA detection. Overall, this approach represents a significant advance over conventional Cas13 systems, offering improved specificity without compromising sensitivity. Its versatility makes it a promising tool for next-generation molecular diagnostics and precision gene editing applications. GRAPHICAL

10 September 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
ARAgustín Robles-Remacho
Agustín Robles-Remacho
IMIsmael Martos-Jamai
Ismael Martos-Jamai
MCMavys Tabraue Chávez
Mavys Tabraue Chávez
AAAraceli Aguilar-González
Araceli Aguilar-González
JLJosé Antonio Laz-Ruiz
José Antonio Laz-Ruiz
RSRosario María Sánchez-Martín
Rosario María Sánchez-Martín
MicroRNAs (miRNAs) are considered potential biomarkers due to their specific expression patterns in tissues and their changes in expression under pathological conditions. MicroRNA-122 (miR-122) is a vertebrate-specific miRNA known for its high expression in the liver, where it plays a role in hepatic metabolism, liver development and cellular differentiation. Dysregulation of miR-122 has been found in pathological conditions such as hepatocellular carcinoma or drug-induced liver injury (DILI). Currently, miRNA detection faces challenges such as improving point-of-care efficiency, obtaining direct results and accurately identifying miRNA isoforms. Overcoming these challenges is essential to improve the clinical efficacy of miR-122 detection as a diagnostic and prognostic biomarker in liver-related diseases. In this study, we present a click chemistry driven dual nanosystem designed for single-base specific miR-122 detection using a flow cytometer as the reading platform. Using the dual nanosystem, we analysed miR-122 expression in various tumour cell lines with specificity and robustness, showing a high correlation with results obtained from a TaqMan assay. We also detected miR-122 using a serum matrix and identified four single nucleotide variations at a specific position within the miR-122 sequence. Our approach involves a fully bioorthogonal strategy and includes signal amplification using two types of different nanoparticles together with the high affinity of peptide nucleic acid probes. The chemistry used in this dual nanosystem offers remarkable versatility and provides a promising opportunity to pioneer enzyme-free nanoparticle-based strategies based on click chemistry and bioorthogonality miRNA detection and isomiR studies, thus advancing the field of molecular diagnostics.